POULLENOT, Florian; OLLIVIER, Julien; RIVIÈRE, Pauline; SAUVAGET, Lucie; BERRONEAU, Aude; DJABAROUTI, Sarah; XUEREB, Fabien; ZERBIB, Frank; BREILH, Dominique; LAHARIE, David

doi:10.1016/j.dld.2019.11.018

Langue

Article de revue

Ce document a été publié dans

Digestive and Liver Disease. 2020-01-01, vol. 52, n° 4, p. 408-413

Résumé en anglais

According to infliximab (IFX) license in Crohn's disease (CD), infusion doses are based on patient's body-weight. Dose banding providing standardized doses (SD) has been implemented in parenteral chemotherapy in order to optimize aseptic unit capacity and reduce drug expenditure, duration of hospital stay and costs without decreasing efficacy. The first part was a single-center retrospective analysis of consecutive CD patients receiving IFX maintenance therapy to determine standardized doses covering more than 50% of infusions. The second part was a prospective cohort study assessing the impact of SD compared to body-weight doses (BWD) on admission duration and costs. Six IFX SD covering more than 90% of infusion doses were implemented for dose banding. According to the Monte-Carlo simulation, there was no significant difference between IFX SD and BWD maintenance regimens. When assessed prospectively in 116 patients (75 patients treated with SD and 41 with BWD) corresponding to 128 infusions, hospitalization duration was shortened by 70 min per patient (p < 0.001). According to a pharmacokinetic model, IFX SD has a pharmacokinetic profile close to BWD and is associated with reduced length of hospitalization in a cohort of patients with CD. IFX SD implementation could optimize infusion units functioning and, save time and costs without decreasing efficacy.< Réduire

Mots clés en anglais

Crohn’s disease

Dose banding

Infliximab

Modelling

Monte-Carlo simulation

Pharmacokinetic

URI

https://oskar-bordeaux.fr/handle/20.500.12278/26094

DOI

http://dx.doi.org/10.1016/j.dld.2019.11.018

Unités de recherche

Biologie des maladies cardiovasculaires (BMC) - UMR 1034

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche